BIOR - FDA clears Biora to begin Phase 1 testing of ulcerative colitis treatment
2023-11-30 17:10:39 ET
More on Biora Therapeutics
- Biora Therapeutics, Inc. (BIOR) Q3 2023 Earnings Call Transcript
- Biora submits updated IND application to FDA for BT-600
- Biora IND for BT-600 delayed due to FDA request for more info
- Seeking Alpha’s Quant Rating on Biora Therapeutics
- Historical earnings data for Biora Therapeutics
For further details see:
FDA clears Biora to begin Phase 1 testing of ulcerative colitis treatment